Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
ACS Central Science
|
April 1, 2021
Broad Spectrum Antibiotic Xanthocillin X Effectively Kills <i>Acinetobacter baumannii</i> <i>via</i> Dysregulation of Heme Biosynthesis
Ines Hübner, Justin A Shapiro, Jörn Hoßmann, et al.
Chemmedchem
|
October 31, 2018
Identification of Specific and Nonspecific Inhibitors of Bacillus anthracis Type III Pantothenate Kinase (PanK)
Justin A Shapiro, John J Varga, Derek Parsonage, et al.
Journal of Medicinal Chemistry
|
February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers
Justin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry
|
August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity
Andrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Biorxiv : the Preprint Server for Biology
|
August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
Shilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature
|
August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
Shilpa Singh, Catherine E Gleason, Min Fang, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
ACS Central Science
|
April 1, 2021
Broad Spectrum Antibiotic Xanthocillin X Effectively Kills <i>Acinetobacter baumannii</i> <i>via</i> Dysregulation of Heme Biosynthesis
Ines Hübner, Justin A Shapiro, Jörn Hoßmann, et al.
Chemmedchem
|
October 31, 2018
Identification of Specific and Nonspecific Inhibitors of Bacillus anthracis Type III Pantothenate Kinase (PanK)
Justin A Shapiro, John J Varga, Derek Parsonage, et al.
Journal of Medicinal Chemistry
|
February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers
Justin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry
|
August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity
Andrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Biorxiv : the Preprint Server for Biology
|
August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
Shilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature
|
August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
Shilpa Singh, Catherine E Gleason, Min Fang, et al.
Page
of 2